Jinling Pharmaceutical Company Limited (SHE:000919)
China
· Delayed Price · Currency is CNY 7.42
+0.04 (0.54%)
At close: Mar 10, 2026
SHE:000919 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 32.11 | 40.41 | 106.19 | 105.28 | 120.63 | 65.14 | Upgrade
|
| Depreciation & Amortization | 150.16 | 150.16 | 151.2 | 124.34 | 122.95 | 119.88 | Upgrade
|
| Other Amortization | 18.96 | 18.96 | 7.06 | 6.04 | 5.31 | 1.19 | Upgrade
|
| Loss (Gain) From Sale of Assets | -21.34 | -21.34 | 0.56 | -62.58 | -51.98 | -0.17 | Upgrade
|
| Asset Writedown & Restructuring Costs | 96.32 | 96.32 | 0.15 | 0.84 | 47.53 | 51.14 | Upgrade
|
| Loss (Gain) From Sale of Investments | -54 | -54 | -32.11 | 12.26 | 2.86 | 14.21 | Upgrade
|
| Provision & Write-off of Bad Debts | 1.76 | 1.76 | 3.2 | 1.66 | -1.67 | 5.01 | Upgrade
|
| Other Operating Activities | 109.31 | -19.92 | 24.05 | 9.15 | 35.27 | 24.87 | Upgrade
|
| Change in Accounts Receivable | -90.63 | -90.63 | 88.99 | -56.17 | -107.93 | -110.36 | Upgrade
|
| Change in Inventory | 18.79 | 18.79 | -27.94 | 7.99 | -30.04 | 20.18 | Upgrade
|
| Change in Accounts Payable | 11.01 | 11.01 | -100.18 | 129.54 | 148.97 | 125.27 | Upgrade
|
| Operating Cash Flow | 275.13 | 154.19 | 212.02 | 260.59 | 292.03 | 311.46 | Upgrade
|
| Operating Cash Flow Growth | 46.51% | -27.28% | -18.64% | -10.76% | -6.24% | -33.14% | Upgrade
|
| Capital Expenditures | -106.35 | -201.63 | -237.88 | -309.64 | -162.76 | -291.41 | Upgrade
|
| Sale of Property, Plant & Equipment | 21.48 | 22.1 | 23.67 | 80.06 | 64.93 | 0.51 | Upgrade
|
| Cash Acquisitions | -261.2 | -261.2 | - | -21.77 | - | - | Upgrade
|
| Divestitures | - | - | - | - | -1.25 | - | Upgrade
|
| Investment in Securities | -227.89 | -313.9 | -276.43 | 4.89 | 0.56 | -120.71 | Upgrade
|
| Other Investing Activities | 38.57 | 36.92 | 40.74 | 25.35 | 29.4 | 34.09 | Upgrade
|
| Investing Cash Flow | -535.37 | -717.7 | -449.89 | -221.11 | -69.12 | -377.51 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 1.96 | 15 | - | Upgrade
|
| Long-Term Debt Issued | - | 150 | 0.31 | - | - | - | Upgrade
|
| Total Debt Issued | 150 | 150 | 0.31 | 1.96 | 15 | - | Upgrade
|
| Long-Term Debt Repaid | - | -3.96 | -5.01 | -22.83 | -1.37 | - | Upgrade
|
| Net Debt Issued (Repaid) | 146.04 | 146.04 | -4.7 | -20.86 | 13.63 | - | Upgrade
|
| Issuance of Common Stock | 1.37 | 744 | 3.38 | 23.62 | - | 2.55 | Upgrade
|
| Repurchase of Common Stock | -18.76 | -18.76 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -70.79 | -63.24 | -51.16 | -51.16 | -50.66 | -90.28 | Upgrade
|
| Other Financing Activities | -13.93 | -1.62 | 8.93 | 2.15 | -2.61 | -2.1 | Upgrade
|
| Financing Cash Flow | 43.92 | 806.42 | -43.55 | -46.26 | -39.65 | -89.83 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.04 | 0.04 | 0.02 | 0.08 | -0 | 0 | Upgrade
|
| Net Cash Flow | -216.29 | 242.94 | -281.4 | -6.71 | 183.26 | -155.87 | Upgrade
|
| Free Cash Flow | 168.78 | -47.44 | -25.85 | -49.05 | 129.26 | 20.06 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | 544.48% | -94.10% | Upgrade
|
| Free Cash Flow Margin | 5.39% | -1.45% | -0.81% | -1.84% | 4.60% | 0.80% | Upgrade
|
| Free Cash Flow Per Share | 0.27 | -0.08 | -0.05 | -0.10 | 0.26 | 0.04 | Upgrade
|
| Cash Income Tax Paid | 98.18 | 92.04 | 128.02 | 97.66 | 104.08 | 98.68 | Upgrade
|
| Levered Free Cash Flow | 178.53 | -80.2 | 12.52 | -134.95 | 55.68 | -0.17 | Upgrade
|
| Unlevered Free Cash Flow | 181.63 | -78.83 | 13.33 | -134.79 | 55.86 | 0.07 | Upgrade
|
| Change in Working Capital | -58.16 | -58.16 | -48.27 | 63.6 | 11.12 | 30.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.